Efficacy and safety of emerging immunotherapies in psoriasis.

Abstract

Psoriasis is a common chronic inflammatory disease of the skin. Current biologic therapies are highly effective in the treatment of psoriasis, transforming the lives of patients with this significantly disabling disease. Advances in the understanding of the immunological pathogenesis of psoriasis have led to the development of new biologic therapies, targeting specific inflammatory cytokines upregulated in psoriasis. These include the IL-17 antagonists, secukinumab, brodalumab and ixekizumab; the IL-23 antagonists, guselkumab and tildrakizumab; and the oral small molecule therapies, tofacitinib and apremilast. Here, we review evidence for the efficacy and safety of these novel psoriasis therapies, providing clinicians with an overview of the next era in immunotherapy for psoriasis.

• Authors: Zenas Z N Yiu, Richard B Warren
• Journal: Immunotherapy (Immunotherapy) Vol. 7 Issue 2 Pg. 119-33 ( 2015) ISSN: 1750-7448 [Electronic] England
• PMID: 25713988 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Antibodies, Monoclonal
• Interleukin-17
• Interleukin-23

Topics

• Antibodies, Monoclonal (immunology, therapeutic use)
• Humans
• Immunotherapy (methods)
• Interleukin-17 (antagonists & inhibitors, immunology)
• Interleukin-23 (antagonists & inhibitors, immunology)
• Psoriasis (drug therapy, immunology, pathology)
• Skin (immunology, pathology)